NewAmsterdam Pharma (NAMS) Other Operating Expenses (2025)
NewAmsterdam Pharma's (NAMS) quarterly Other Operating Expenses came in at -$1000.0 in Q3 2025.
NewAmsterdam Pharma (NAMS) Other Operating Expenses (2025) Analysis & Trends
NewAmsterdam Pharma has disclosed Other Operating Expenses across 1 years of filings, most recently posting -$1000.0 for Q3 2025.
- Other Operating Expenses for Q3 2025 came in at -$1000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$1000.0 (changed N/A YoY), and the FY2022 annual result was $61.8 million, changed N/A from the prior year.
- Other Operating Expenses came in at -$1000.0 for Q3 2025 at NewAmsterdam Pharma.
- In the past five years, Other Operating Expenses ranged from a high of -$1000.0 in Q3 2025 to a low of -$1000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | NewAmsterdam Pharma | 3.63 Bn | 3.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1,000.00 |